Condition
Metastases clinical trials and research
As of November 12, 2026, Find a Trial lists 6 Metastases clinical trials that are recruiting, at sites in 4 countries (most in China (2), United States (2), Germany (1)). By phase: Phase 2 (2), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 4Countries
Newest Metastases clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| LATTICE radiotherapy vs moderately dose-escalated palliative radiation for metastases | Phase 2 | Palo Alto, California | Recruiting | May 18, 2026 |
| Zanidatamab with pembrolizumab and chemotherapy for HER2- and PD-L1-positive metastatic gastroesophageal adenocarcinoma | Phase 2 | Berlin and 19 other locations | Recruiting | Sep 16, 2025 |
| New imaging technology for identifying breast cancer and lymph node status | — | Kunming, Yunnan | Recruiting | Dec 3, 2024 |
| Long-term assessment of local therapy for oligometastatic disease | — | Copenhagen, Capital Region of Denmark and 10 other locations | Recruiting | Apr 10, 2024 |
| Using Y-90 radioembolization to improve liver function before surgery for colorectal cancer spread to the liver | Phase 1 | Houston, Texas | Recruiting | Jan 19, 2022 |
| Evaluating 68Ga-PSMA PET for advanced renal cancer diagnosis | — | Lanzhou, Gansu and 8 other locations | Recruiting | Aug 3, 2021 |
All recruiting trials (6)
-
LATTICE radiotherapy vs moderately dose-escalated palliative radiation for metastases
This study tests whether LATTICE radiotherapy given in 5 fractions works better than a standard palliative dose for patients with metastatic cancer who have 1–2 sizable tumors.
-
Zanidatamab with pembrolizumab and chemotherapy for HER2- and PD-L1-positive metastatic gastroesophageal adenocarcinoma
This trial tests whether adding zanidatamab to pembrolizumab plus chemotherapy helps people with untreated HER2- and PD-L1-positive metastatic gastroesophageal adenocarcinoma.
-
New imaging technology for identifying breast cancer and lymph node status
This study is testing a new imaging technology to help doctors better identify breast cancer and check lymph nodes during surgery for patients with breast cancer.
-
Long-term assessment of local therapy for oligometastatic disease
This study is testing different local treatments for people with oligometastatic cancer to see how well they work over time and to help choose the best options for patients.
-
Using Y-90 radioembolization to improve liver function before surgery for colorectal cancer spread to the liver
This study is testing if a treatment called Y-90 radioembolization can help patients with colorectal cancer spread to the liver grow enough healthy liver tissue to safely undergo surgery.
-
Evaluating 68Ga-PSMA PET for advanced renal cancer diagnosis
This study is testing if a special imaging technique called 68Ga-PSMA PET can better find advanced kidney cancer spots compared to regular CT scans and see if it helps doctors make better treatment choices for patients.
Related topics
Quick answers
How many Metastases clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in China (2 trials), United States (2 trials), Germany (1 trial), Denmark (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.